Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age12-24
SponsorUniversity of Colorado, Denver

About this trial

The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.

Eligibility criteria

Qualifiers

Signed and dated informed consent form

Willingness to comply with all study procedures and availability for the duration of the study

Male or female biological sex, age 12 through 24 years

In the preoperative pathway for vertical sleeve gastrectomy

Disqualifiers

Planned Roux-en-Y gastric bypass

Hypothalamic obesity

Type 2 Diabetes

Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)

Trial design

Treatments tested in this trial

  • Injectable semaglutide
  • Standard postoperative care

Treatment groups

40 Participants
are divided into 3 treatment groups

Sponsors and collaborators

University of Colorado, Denver

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator